Mealey's (January 4, 2018, 3:27 PM EST) -- WASHINGTON, D.C. — In a Dec. 15 response brief, a patent challenger tells the Federal Circuit U.S. Court of Appeals that the Patent Trial and Appeal Board erred in finding no motivation to combine various prior art to arrive at an invention claiming chimeric antigen receptor (CAR) immunotherapy (Kite Pharma Inc. v. Sloan-Kettering Institute for Cancer Research, No. 17-1647, Fed. Cir.)....